High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors
作者:Stephanie M. Myers、Ruth H. Bawn、Louise C. Bisset、Timothy J. Blackburn、Betty Cottyn、Lauren Molyneux、Ai-Ching Wong、Celine Cano、William Clegg、Ross. W. Harrington、Hing Leung、Laurent Rigoreau、Sandrine Vidot、Bernard T. Golding、Roger J. Griffin、Tim Hammonds、David R. Newell、Ian R. Hardcastle
DOI:10.1021/acscombsci.5b00155
日期:2016.8.8
The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57 617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active
细胞外相关激酶5(ERK5)是癌症治疗的有希望的目标。基于IMAP FP渐进结合系统,针对ERK5开发了高通量筛选,并用于从57 617种化合物的文库中鉴定命中。筛选命中明显有四个不同的化学系列。命中的重新合成和重新测定表明,一个系列没有返回活性化合物,而三个系列返回了活性命中。结构活性研究表明,4-苯甲酰基吡咯-2-羧酰胺药效团具有很好的进一步开发潜力。鉴定了最小的激酶结合药效基团,关键实例证明了对ERK5的选择性优于p38α激酶。